Events, Pharmaceutical

Aptar Pharma Sponsor & Exhibitor at DDL 2021 Virtual Conference December 8-10

Aptar Pharma will showcase our expanded portfolio of respiratory innovations and services at this year’s three-day online conference.

December 8 – December 10, 2021 9:00 AM London / 4:00 AM New York
Register for DDL 2021
22 Nov 2021

Aptar Pharma is pleased to be a sponsor and online exhibitor at this this year’s Drug Delivery to the Lung (DDL) Conference 2021, which takes place from December 8-10.

A worldwide leader in respiratory drug delivery devices for the treatment of asthma and COPD, Aptar Pharma will virtually showcase our latest drug delivery innovations and services for respiratory devices at the three-day online conference, along with experts from our Aptar Pharma Services companies Nanopharm and Next Breath.

Our respiratory and pulmonary experts will be on hand via online chat to engage with this year’s conference delegates about our innovative range of respiratory drug delivery systems and connected devices that help improve adherence and patient health outcomes.

A highlight for Aptar Pharma at DDL 2021 will be a Podium Talk entitled “Targeted Nasal Drug Delivery: for Nose, Body and Brain”, which will be presented by Dr. Julie D. Suman, President of Next Breath, an Aptar Pharma company on December 10 from 12:30 pm to 12:55 pm.

To further share our expertise in respiratory drug delivery with the scientific community, Aptar Pharma will be presenting four scientific posters during DDL 2021:

  • “Identification of Potential Antioxidant Degradation Products as Extractables from an Innovative Thermo Plastic Elastomer used in MDIs” – Claire Cannette, Aptar Pharma
  • “Fundamental Properties of Propellant Aerosols can Guide Transition to Low Global Warming Potential pMDIs: Size, Velocity and Surface Charge” – Irene​ Rossi & William J Ganley, Nanopharm, an Aptar Pharma Company
  • “Development of a Nasal Spray Containing a Novel Human Recombinant Antibody for SARS-CoV-2 Therapy” – Antonia Zapata del Baño, Nanopharm, an Aptar Pharma Company
  • “The Application of Morphological Filters in Automated Imaging of Nasal Products: a Design of Experiment Approach” – Paulo​ Serra, Nanopharm, an Aptar Pharma Company.

DDL, the premier conference and industry exhibition dedicated to pulmonary and nasal drug delivery, has been running for more than 30 years and will take place online for the second year.

To register and find out more information, click here.

Back To Top